1. Home
  2. NRIX vs ATUS Comparison

NRIX vs ATUS Comparison

Compare NRIX & ATUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • ATUS
  • Stock Information
  • Founded
  • NRIX 2009
  • ATUS 2015
  • Country
  • NRIX United States
  • ATUS United States
  • Employees
  • NRIX N/A
  • ATUS N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • ATUS Cable & Other Pay Television Services
  • Sector
  • NRIX Health Care
  • ATUS Telecommunications
  • Exchange
  • NRIX Nasdaq
  • ATUS Nasdaq
  • Market Cap
  • NRIX 952.9M
  • ATUS 1.1B
  • IPO Year
  • NRIX 2020
  • ATUS 2017
  • Fundamental
  • Price
  • NRIX $11.49
  • ATUS $2.00
  • Analyst Decision
  • NRIX Strong Buy
  • ATUS Buy
  • Analyst Count
  • NRIX 16
  • ATUS 7
  • Target Price
  • NRIX $30.44
  • ATUS $2.75
  • AVG Volume (30 Days)
  • NRIX 796.7K
  • ATUS 2.7M
  • Earning Date
  • NRIX 07-10-2025
  • ATUS 07-31-2025
  • Dividend Yield
  • NRIX N/A
  • ATUS N/A
  • EPS Growth
  • NRIX N/A
  • ATUS N/A
  • EPS
  • NRIX N/A
  • ATUS N/A
  • Revenue
  • NRIX $56,417,000.00
  • ATUS $8,855,764,000.00
  • Revenue This Year
  • NRIX $16.69
  • ATUS N/A
  • Revenue Next Year
  • NRIX N/A
  • ATUS N/A
  • P/E Ratio
  • NRIX N/A
  • ATUS N/A
  • Revenue Growth
  • NRIX N/A
  • ATUS N/A
  • 52 Week Low
  • NRIX $8.18
  • ATUS $1.52
  • 52 Week High
  • NRIX $29.56
  • ATUS $3.20
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 50.78
  • ATUS 36.13
  • Support Level
  • NRIX $12.25
  • ATUS $1.95
  • Resistance Level
  • NRIX $12.00
  • ATUS $2.15
  • Average True Range (ATR)
  • NRIX 0.69
  • ATUS 0.11
  • MACD
  • NRIX -0.08
  • ATUS -0.02
  • Stochastic Oscillator
  • NRIX 21.57
  • ATUS 10.23

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About ATUS Altice USA Inc.

Altice Europe acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and business in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.

Share on Social Networks: